Literature DB >> 17594363

Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.

Michael Koutsilieris1, Theodore Dimopoulos, Constantine Milathianakis, John Bogdanos, Dimitrios Karamanolakis, Nicholas Pissimissis, Antonis Halapas, Peter Lembessis, Andreas Papaioannou, Antigone Sourla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17594363     DOI： 10.1111/j.1464-410X.2007.06958.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  2 in total

1.  [Change of the LHRH analogue in progressive castration-refractory prostate cancer].

Authors:  A Heidenreich; D Porres; R Epplen; T van Erps; D Pfister
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

2.  Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells.

Authors:  Efstathia Papageorgiou; Nea Pitulis; Menelaos Manoussakis; Peter Lembessis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.